NitroMed, Inc. Promotes Michael Sabolinski, M.D. To The Position Of Chief Medical Officer

LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 6, 2006--NitroMed, Inc. (NASDAQ:NTMD) announced that Michael L. Sabolinski, M.D. has been named Chief Medical Officer for the Company effective today. Dr. Sabolinski succeeds company co-founder Manuel Worcel, M.D. in this position. As Chief Medical Officer, Dr. Sabolinski will oversee Clinical Research, Regulatory Affairs, Medical Affairs and Quality Assurance, serve on the Executive Committee and report to Michael D. Loberg, Ph.D., President and Chief Executive Officer.
MORE ON THIS TOPIC